Projects per year
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease characterized by severe neurologic and somatic disease caused by deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes the glycosaminoglycans heparan and dermatan sulphate. Intravenous enzyme replacement therapy (ERT) currently constitutes the only approved therapeutic option for MPSII. However, the inability of recombinant IDS to efficiently cross the blood-brain barrier (BBB) limits ERT efficacy in treating neurological symptoms. Here, we report a gene therapy approach for MPSII through direct delivery of vectors to the CNS. Through a minimally invasive procedure, we administered adeno-associated virus vectors encoding IDS (AAV9-Ids) to the cerebrospinal fluid of MPSII mice with already established disease. Treated mice showed a significant increase in IDS activity throughout the encephalon, with full resolution of lysosomal storage lesions, reversal of lysosomal dysfunction, normalization of brain transcriptomic signature, and disappearance of neuroinflammation. Moreover, our vector also transduced the liver, providing a peripheral source of therapeutic protein that corrected storage pathology in visceral organs, with evidence of cross-correction of nontransduced organs by circulating enzyme. Importantly, AAV9-Ids-treated MPSII mice showed normalization of behavioral deficits and considerably prolonged survival. These results provide a strong proof of concept for the clinical translation of our approach for the treatment of Hunter syndrome patients with cognitive impairment.
|Number of pages||19|
|Publication status||Published - 16 Jun 2016|
- Disease Models, Animal
- Genetic Therapy
- Genetic Vectors
- Iduronate Sulfatase/genetics
- Mice, 129 Strain
- Mice, Inbred C57BL
- Mucopolysaccharidosis II/therapy
FingerprintDive into the research topics of 'CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)'. Together they form a unique fingerprint.
- 1 Finished
Desarrollo de terapias génicas mínimamente invasivas para el tratamiento de la Mucopolisacaridos tipo IIIA, IIIB, IIIC y IIID y tipo II.
17/12/12 → 31/12/15
Project: Research Projects and Other Grants